Ovarian cancer: Paclitaxel is indicated: as first-line chemotherapy for the treatment of ovarian cancer in patients with advanced ovarian cancer or residual tumours (>1 cm) after preceding laparotomy, in combination with cisplatin; for second-line chemotherapy of metastatic ovarian cancer in patients who have failed conventional therapeutic treatment with platinum-containing agents.
Breast cancer: Paclitaxel is indicated for initial treatment of advanced or metastatic breast cancer in combination with trastuzumab in patients overexpressing HER-2 at 3+ level (immunohistochemical evidence) for whom anthracycline therapy is not indicated (see Pharmacology: Pharmacodynamics under Actions and Precautions).
Paclitaxel given as a single agent is indicated for the treatment of metastatic breast cancer in patients where standardised anthracycline therapy has either failed or is not suitable.
Advanced non-small-cell lung cancer: Paclitaxel in combination with cisplatin is indicated for the treatment of non-small cell lung cancer in patients for whom a potentially curative surgical treatment and/or radiation therapy is not suitable.
Only insufficient data on the efficiency of paclitaxel for this indication are available; a summary of relevant trials is contained in Pharmacology: Pharmacodynamics under Actions.